JNJPharmaceuticals
FollowFollowingUnfollowFree · no card
Get what investors say about JNJ next
6 investor calls on JNJ in the last 90 days (6 bullish, 0 bearish). Follow JNJ free and new calls come to you in The Brief, our morning email, the day after we record them. This page shows them a week later.
or continue with Google ·
Who said what, and what JNJ did next
Every dot is a day someone on the record made a call. Hover one to see who. We are not scoring them — the point is that you can see it and judge for yourself.
Who’s talking about JNJ
| Date | Voice | Stance | Venue | Thesis |
|---|---|---|---|---|
| 2026-10-26 | Ayako Yoshiyoka | Bullish | Fox Business (uncut) | Johnson & Johnson offers healthcare diversification often overlooked in AI narratives, with a strong recent… |
| 2026-10-20 | Jim Cramer (CNBC)Host, CNBC's Mad Money | Bullish | CNBC (uncut) | Johnson & Johnson is suitable for investing for young children because its triple-A balance sheet provides… |
| 2026-10-15 | Jim Cramer (CNBC)Host, CNBC's Mad Money | Bullish | CNBC (uncut) | J&J's post-earnings selloff was an overreaction to weakness in a single MedTech division; the AAA balance… |
| 2026-10-14 | Joe Wolk | Bullish | Fox Claman Countdown (playlist) | J&J raises full-year guidance with oncology on track to double from ~$25B to ~$50B, the DePuy Synthes… |
| 2026-10-14 | Jared HolzManaging Director and Healthcare Equity Strategist, Mizuho | Bullish | CNBC (uncut) | Despite near-term medical device headwinds, J&J's pharma segment stands as one of the best pipelines in… |
| 2026-10-08 | Joaquin DuatoChairman & CEO, Johnson & Johnson | Bullish | David Rubenstein (newest) | J&J is at the early innings of a multi-year growth cycle with line-of-sight to double-digit revenue growth by… |
| 2026-07-06 | Jim Cramer (CNBC)Host, CNBC's Mad Money | Bullish | CNBC Television | Rotation-driven selloff from $263 to $256 is a dislocation unrelated to fundamentals — J&J is a pure-play… |
| 2020-07-05 | Peter LynchFormer manager, Fidelity Magellan Fund | Bullish | Investor Talk | JNJ was irrationally sold off from 58 to 36 on health care reform fears despite 60% of earnings being outside… |
Next report: 26 Jan 2027 after the close
| Report | When | EPS actual vs est. | Reaction |
|---|---|---|---|
| 13 Oct 2026 | before the open | 2.59 vs 2.56 | -5.8% |
Notable options days
Sessions in the last 120 where JNJ’s settled options volume ran ≥ 2× its trailing 20-session baseline, or delta-dollar flow ran ≥ 2.5× — 9 of 120 sessions qualified.
| Date | Close | RVOL | Δ$ flow ($M) | Call % | LEAPS % | +20 sess. |
|---|---|---|---|---|---|---|
| 2026-10-22 | ||||||
| 2026-10-14 | ||||||
| 2026-10-13 | ||||||
| 2026-10-12 | ||||||
| 2026-08-24 | ||||||
| 2026-08-18 | ||||||
| 2026-07-23 | ||||||
| 2026-07-07 | ||||||
| 2026-05-22 |
JNJ on the Wheel
JNJ passed our 1-month put test (30-delta put, 30–45 days, sold at the bid, bought back at half the credit), 2021–2026.
The Wheel lists cash-secured puts on stocks after a 3% drop, with live quotes, the chance of assignment and each stock’s own history. Free to use; a free account lets you follow stocks, add your own and ask questions.
Decision support, not advice · questions put sellers ask us
Idea Scout
Following JNJ? Every Sunday we read the tape so you don't have to — who's recommending what, where they agree, and who just changed their mind. One free email a week.
Free · double opt-in · unsubscribe in one click